vadimezan has been researched along with acridines in 2 studies
| Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (acridines) | Trials (acridines) | Recent Studies (post-2010) (acridines) |
|---|---|---|---|---|---|
| 272 | 16 | 101 | 6,987 | 169 | 856 |
| Protein | Taxonomy | vadimezan (IC50) | acridines (IC50) |
|---|---|---|---|
| Acetylcholinesterase | Homo sapiens (human) | 6.84 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Denny, WA; Lee, HH; Li, AE; Patterson, LH; Pullen, SM; Thompson, KM; Wilson, WR | 1 |
| Chiang, D; Kestell, P; Lewis, DF; Paxton, JW; Zhou, S | 1 |
2 other study(ies) available for vadimezan and acridines
| Article | Year |
|---|---|
Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N.
Topics: Acridines; Animals; Anthraquinones; Antineoplastic Agents; Cell Survival; Humans; Intercalating Agents; Mammary Neoplasms, Experimental; Mice; Nitracrine; Oxidation-Reduction; Prodrugs; Xanthenes; Xanthones | 1996 |
Inhibition of human CYP1A2 oxidation of 5,6-dimethyl-xanthenone-4-acetic acid by acridines: a molecular modelling study.
Topics: Acridines; Binding Sites; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Humans; Models, Molecular; Molecular Structure; Oxidation-Reduction; Structure-Activity Relationship; Xanthones | 2005 |